Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 6/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | RET | P07949 | 5/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 0.67 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.63 |
| ▸ | FLT1 | P17948 | 4/20 | 0.61 |
| ▸ | CSF1R | P07333 | 4/20 | 0.61 |
| ▸ | FLT4 | P35916 | 4/20 | 0.61 |
| ▸ | AURKA | O14965 | 3/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.61 |
| ▸ | STK3 | Q13188 | 3/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.61 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001446 | 1.00 | FGFR1 (1.00) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL5390359 | 1.00 | FGFR1 (1.00) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL19255670 | 0.87 | PDGFRB (0.77) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL5373629 | 0.86 | PDGFRB (0.76) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL6391018 | 0.85 | PDGFRB (0.74) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL6389339 | 0.85 | PDGFRB (0.74) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL5376617 | 0.85 | PDGFRB (0.74) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL5567713 | 0.85 | ALK (0.76) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL31727052 | 0.85 | FLT3 (0.74) | FGFR1FLT3PDGFRBRETALK | |
| SCHEMBL31727096 | 0.85 | PDGFRB (0.74) | FGFR1FLT3PDGFRBRETALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | claimed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-9439961-B2 | Pharmaceutical composition for treating ischemic events | NIIGATA UNIVERSITY (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20140127233-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS | NIIGATA UNIVERSITY (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| EP-1981851-B1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | FGFR1 350/4885FLT3 526/4885PDGFRB 2508/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | FGFR1 4752/4885FLT3 4311/4885PDGFRB 4421/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | FGFR1 21/4885FLT3 30/4885PDGFRB 13/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | FGFR1 350/4885FLT3 526/4885PDGFRB 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.